Ying Qin1, Yi Zhang2, Peng Wu3, Shuo Feng3, Jiandong Zheng1, Peng Yang2, Yang Pan2, Quanyi Wang2, Luzhao Feng1, Xinghuo Pang2, Joan Puig-Barberà4, Hongjie Yu5, Benjamin J Cowling6. 1. Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China. 2. Beijing Center for Disease Prevention and Control, Beijing, China. 3. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. 4. Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO - Public Health, Valencia, Spain. 5. Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: yuhj@chinacdc.cn. 6. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: bcowling@hku.hk.
Abstract
BACKGROUND: Estimates of influenza vaccination effectiveness (VE) are valuable for populations where the vaccine has been promoted in order to support vaccination policy and to permit evaluation of vaccination strategies. Such studies would be important for China due to limited data available during seasons when the vaccine strains matched or mismatched the circulating viruses. METHODS: We conducted a test-negative study in hospitals in Beijing. Patients admitted to five hospitals in the city were enrolled during the winter influenza seasons of 2013-14 and 2014-15. Influenza virus infections were determined by PCR, and influenza vaccination records were extracted from a centralized electronic immunization registry. Influenza VE was estimated by logistic regression adjusting for age group, sex and chronic conditions, and matched by calendar week. RESULTS: A total of 2368 inpatients were recruited during the study period with a vaccination coverage in the control group of 12.8%. The overall estimate of influenza VE was 46.9% (95% CI: -20.4%, 76.6%) for the 2013-14 season and 5.0% (95% CI: -53.0%, 41.0%) for the 2014-15 season. Estimates of VE were relatively higher in children aged 6-17 years than older persons across two influenza seasons while estimates of VE for both adults and elderly were relatively low. CONCLUSIONS: Our findings were consistent with expected influenza vaccination effectiveness in seasons when the vaccine matched or mismatched circulating viruses. Strategies to increase influenza vaccine coverage could provide a public health benefit.
BACKGROUND: Estimates of influenza vaccination effectiveness (VE) are valuable for populations where the vaccine has been promoted in order to support vaccination policy and to permit evaluation of vaccination strategies. Such studies would be important for China due to limited data available during seasons when the vaccine strains matched or mismatched the circulating viruses. METHODS: We conducted a test-negative study in hospitals in Beijing. Patients admitted to five hospitals in the city were enrolled during the winter influenza seasons of 2013-14 and 2014-15. Influenzavirus infections were determined by PCR, and influenza vaccination records were extracted from a centralized electronic immunization registry. Influenza VE was estimated by logistic regression adjusting for age group, sex and chronic conditions, and matched by calendar week. RESULTS: A total of 2368 inpatients were recruited during the study period with a vaccination coverage in the control group of 12.8%. The overall estimate of influenza VE was 46.9% (95% CI: -20.4%, 76.6%) for the 2013-14 season and 5.0% (95% CI: -53.0%, 41.0%) for the 2014-15 season. Estimates of VE were relatively higher in children aged 6-17 years than older persons across two influenza seasons while estimates of VE for both adults and elderly were relatively low. CONCLUSIONS: Our findings were consistent with expected influenza vaccination effectiveness in seasons when the vaccine matched or mismatched circulating viruses. Strategies to increase influenza vaccine coverage could provide a public health benefit.
Authors: Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto Journal: Vaccine Date: 2019-02-07 Impact factor: 3.641
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Marc Rondy; Nathalie El Omeiri; Mark G Thompson; Alain Levêque; Alain Moren; Sheena G Sullivan Journal: J Infect Date: 2017-09-18 Impact factor: 6.072
Authors: Ting F Leung; Renee W Y Chan; Angela Kwok; Wendy C S Ho; Mars K P Tao; Kam L Hon; Frankie W T Cheng; Albert M Li; Paul K S Chan Journal: Influenza Other Respir Viruses Date: 2017-05-25 Impact factor: 4.380
Authors: Angela Domínguez; Núria Soldevila; Diana Toledo; Pere Godoy; Elena Espejo; Maria Amelia Fernandez; José María Mayoral; Jesús Castilla; Mikel Egurrola; Sonia Tamames; Jenaro Astray; María Morales-Suárez-Varela Journal: Euro Surveill Date: 2017-08-24